Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. News
  7. Summary
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eisai : and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Positive EU CHMP Opinions for LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Two Different Types of CancerPositive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Benefit Compared to Sunitinib in CLEAR/KEYNOTE-581 TrialPositive Opinion Granted for Advanced Endometrial Carcinoma Based on Significant OS and PFS Benefit

10/17/2021 | 07:42pm EST
News release searchSearch

Disclaimer

Eisai Co. Ltd. published this content on 18 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 October 2021 23:41:01 UTC.


© Publicnow 2021
All news about EISAI CO., LTD.
07:13aMerck, Eisai Get Europe OK for Lenvima/Keytruda Combination in Two Cancers
DJ
11/28European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) for Pat..
AQ
11/28European Commission Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as Firs..
AQ
11/28EISAI : European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) ..
PU
11/28EISAI : European Commission Approves LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) ..
PU
11/19EISAI : Selected for membership in dow jones sustainability asia pacific index 2021 for ei..
PU
11/18Biogen Inc. - Update on Regulatory Review of Aducanumab in the European Union
AQ
11/18Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award
AQ
11/18Nikkei dips but pares losses after report on larger stimulus
RE
11/17EISAI : RECEIVES THE “MOST LIKED!” IR AWARD AT THE 2021 IR AWARD
PU
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Financials
Sales 2022 708 B 6 225 M 6 225 M
Net income 2022 57 052 M 502 M 502 M
Net cash 2022 147 B 1 297 M 1 297 M
P/E ratio 2022 35,4x
Yield 2022 2,29%
Capitalization 2 020 B 17 767 M 17 766 M
EV / Sales 2022 2,65x
EV / Sales 2023 2,56x
Nbr of Employees 11 237
Free-Float 87,9%
Chart EISAI CO., LTD.
Duration : Period :
Eisai Co., Ltd. Technical Analysis Chart | 4523 | JP3160400002 | MarketScreener
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Last Close Price 7 045,00 JPY
Average target price 10 150,77 JPY
Spread / Average Target 44,1%
EPS Revisions
Managers and Directors
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer
Yasuhiko Katoh Chairman
Edward Stewart Geary Chief Medical Officer & Managing Executive Officer
Lynn D. Kramer Chief Medical & Chief Clinical Officer-Neurology
Sector and Competitors
1st jan.Capi. (M$)
EISAI CO., LTD.-4.44%18 096
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049